Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection

Details for Australian Patent Application No. 2004287482 (hide)

International Classifications

Event Publications

15 June 2006 PCT application entered the National Phase

PCT publication WO2005/044306 Priority application(s): WO2005/044306

6 March 2008 Assignment before Grant

Chiron Corporation The application has been assigned to Novartis Vaccines and Diagnostics, Inc.

5 November 2009 Alteration of Name

The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

14 April 2011 Application Accepted

Published as AU-B-2004287482

11 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.